CIK 0001750284 · Non-accelerated filer<br>Smaller reporting company
Olema Oncology, Inc.
Sign in to watch- Ticker
- OLMA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 300409740
- Phone
- (415) 651-3316
- Business address
- 365 OYSTER POINT BOULEVARD, SUITE 400, SOUTH SAN FRANCISCO, CA, 94080
- Former names
- Olema Pharmaceuticals, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 17 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-06-16 | Larson Yi Director | Grant or award · Stock Option (right to buy) | +21,520 | 21,520 | ||
| 2023-06-16 | Horning Sandra Director | Grant or award · Stock Option (right to buy) | +21,520 | 21,520 | ||
| 2023-06-16 | CLARK IAN T Director | Grant or award · Stock Option (right to buy) | +21,520 | 21,520 | ||
| 2023-06-16 | Graham G. Walmsley Director | Grant or award · Stock Option (right to buy) | +21,520 | 21,520 | ||
| 2023-06-16 | Hrustanovic Gorjan Director | Grant or award · Stock Option (right to buy) | +21,520 | 21,520 | ||
| 2023-06-16 | BUTITTA CYNTHIA M Director | Grant or award · Stock Option (right to buy) | +21,520 | 21,520 | ||
| 2023-06-16 | RAPPAPORT ANDREW Director | Grant or award · Stock Option (right to buy) | +21,520 | 21,520 | ||
| 2023-06-16 | BVF PARTNERS L P/IL Director | Grant or award · Stock Option (Right to buy) | +21,520 | 21,520 | ||
| 2023-06-08 | Harmon Cyrus Director | Sale | −10,000 | $6.30 | $63K | 1,038,714 |
| 2023-06-06 | Harmon Cyrus Director | Sale | −5,000 | $6.30 | $31K | 1,048,714 |
| 2023-06-05 | Harmon Cyrus Director | Sale | −5,000 | $6.05 | $30K | 1,053,714 |
| 2023-04-06 | Kovacs Shane William Charles CH. OPERATING & FINANCIAL OFF. | Purchase | +10,000 | 396,197 | ||
| 2023-02-01 | Zojwalla Naseem Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +150,000 | 150,000 | ||
| 2023-02-01 | Moriarty John B EVP, Ch. Legal Officer & Sec. | Grant or award · Stock Option (Right to Buy) | +150,000 | 150,000 | ||
| 2023-02-01 | Myles David C. Chief Development Officer | Grant or award · Stock Option (Right to Buy) | +150,000 | 150,000 | ||
| 2023-02-01 | Kovacs Shane William Charles Ch. Operating & Financial Off. | Grant or award · Stock Option (Right to Buy) | +200,000 | 200,000 | ||
| 2023-02-01 | Horn Kinney Chief Business Officer | Grant or award · Stock Option (Right to Buy) | +150,000 | 150,000 | ||
| 2023-02-01 | Bohen Sean President and CEO | Grant or award · Stock Option (Right to Buy) | +550,000 | 550,000 | ||
| 2023-02-01 | Harmon Cyrus Chief Research Officer | Grant or award · Stock Option (Right to Buy) | +150,000 | 150,000 | ||
| 2022-09-21 | Bohen Sean PRESIDENT AND CEO | Purchase | +20,000 | 74,279 |
Page 13 of 21 · 402 trades